Warfarin and fibrinolysis--a challenging combination: an observational cohort study. - Wikidata - wikimedia - TriplyDB

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

http://www.wikidata.org/entity/Q34825910

about

Bayesian hypothesis testing in two-arm trials with dichotomous outcomes.

P2860

Q44441796-E9FBAE0C-0A9F-4D9D-A258-77C26AE65F44

P2860

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

http://www.wikidata.org/entity/Q34825910

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@ast

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@en

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@nl

type

label

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@ast

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@en

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@nl

prefLabel

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@ast

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@en

Warfarin and fibrinolysis--a challenging combination: an observational cohort study.

@nl

P1433

Q34825910-D33EC535-C432-47FB-986D-D5F53A32D4FF

P1476

Q34825910-6AA8CB1C-5E24-4762-BA0B-04183D15A49C

P2093

Q34825910-48E7C9EA-94D3-40E9-8BCE-6E96E09829CC

Q34825910-4FBFAE8D-11F2-4F70-A0D1-6F1F3565D1BF

Q34825910-674E80B5-E059-41F3-9D1F-9B4A9A937878

Q34825910-85368BBD-F2CF-4E6E-B269-BBFE2E610954

Q34825910-B7AB7418-5DA6-4FCB-B2D2-B9C7E49E8319

P2860

Q34825910-03863F4C-A547-434E-B880-23F054E02810

Q34825910-0584820F-09AF-4405-B063-633871AC9CC9

Q34825910-0659A86F-5236-40D9-BA10-95FE6DFD3C7C

Q34825910-39956FD7-9F62-4C2F-AECA-5693D9DD7630

Q34825910-3F0BFAB9-AA4E-43C3-8C38-17A5FC62D2D4

Q34825910-469D58EB-628C-444C-8DAA-34E33BAD3BC6

Q34825910-4964729E-000D-4275-8A7C-8930C86777DD

Q34825910-4A623DD4-65A3-4222-ADBD-EE586C84920A

Q34825910-4CD9FBD1-B4BC-4803-8925-4C77C5E9013F

Q34825910-645EDB50-5484-4F58-90F6-AF0ECA3CF190

P2888

Q34825910-3C1D9D7A-3F6D-4448-AB61-150294D7FDC3

P304

Q34825910-61635CC1-FF08-4DC1-B3E6-834E6F9347FF

P31

Q34825910-122D129A-2B20-4948-BD70-42017DCC7817

P356

Q34825910-69CED953-191B-4D15-928C-05CBD647CB5F

P478

Q34825910-8806918E-CB72-457F-9133-7BF4943358E0

P50

Q34825910-7A9C5D08-613D-47EE-8663-8438ABB2E45A

P577

Q34825910-EC9FB0E3-AF8A-4CA7-A0FE-185541E7822B

P5875

Q34825910-9B7D68B2-8309-49BB-BB46-DC57D8E1E98D

P6179

Q34825910-57B6DEAE-EFE1-44F9-964F-EA9C40EF4B98

P698

Q34825910-EC1D4E21-BEE2-4E87-8038-50351B6A9749

P932

Q34825910-D0D80ADD-025A-402B-858B-13459534E0D7

P356

1757-7241-19-21

P1433

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine

P1476

Warfarin and fibrinolysis--a challenging combination: an observational cohort study

@en

P2093

Harri Luurila

http://www.w3.org/2001/XMLSchema#string

James Boyd

http://www.w3.org/2001/XMLSchema#string

Jyrki Puolakka

http://www.w3.org/2001/XMLSchema#string

Sini Saarinen

http://www.w3.org/2001/XMLSchema#string

Taneli Väyrynen

http://www.w3.org/2001/XMLSchema#string

P2860

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial

Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.

ST elevation myocardial infarction guidelines today: a systematic review exploring updated ACC/AHA STEMI guidelines and their applications.

2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Is warfarin a contraindication to thrombolysis in acute ST elevation myocardial infarction?

A comparison of reteplase with alteplase for acute myocardial infarction.

Underutilization of evidence-based medications in acute ST elevation myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry.

System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention.

Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project.

P2888

1757-7241-19-21

P304

21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1757-7241-19-21

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51019546

http://www.w3.org/2001/XMLSchema#string

P6179

1046565092

http://www.w3.org/2001/XMLSchema#string

P698

21466702

http://www.w3.org/2001/XMLSchema#string

P932

3080327

http://www.w3.org/2001/XMLSchema#string